April 3, 2012Journal of Cardiovascular Medicine
B-type natriuretic peptide assessment in ambulatory heart failure patients
Key result
BNP assessment fails to increase guideline-recommended HF therapy use in outpatients with reduced LVEF.
- n=15,381
Why the study?
Does BNP assessment or BNP level impact the utilization of guideline-recommended therapies in outpatients with reduced LVEF?
Population
15,381 outpatients ≥18 years of age with LVEF ≤35% and chronic heart failure or previous myocardial…
Comparison
B-type natriuretic peptide (BNP) assessment vs No BNP assessment, or comparison across BNP…
Design
Cohort
Authors
Discussion
Loading...
Member takes
Implication
BNP rarely assessed and unrelated to therapy use in ambulatory HFrEF; leaves open whether routine testing could improve guideline-directed care.
Study Design
Type
Cohort (n=15,381)
Multicenter
Yes
Structured PICO
Does BNP assessment or BNP level impact the utilization of guideline-recommended therapies in outpatients with reduced LVEF?
P
Population
15,381 outpatients ≥18 years of age with LVEF ≤35% and chronic heart failure or previous myocardial infarction.
E
Exposure
B-type natriuretic peptide (BNP) assessment
C
Comparator
No BNP assessment, or comparison across BNP tertiles (≤219 pg/ml, >219 to 649 pg/ml, and >649 pg/ml)
O
Outcome
Frequency of BNP assessment and utilization of guideline-recommended heart failure therapies by BNP level
In outpatients with reduced LVEF, BNP is infrequently measured and its assessment does not appear to drive greater utilization of guideline-directed medical therapy.
Cite This Study
Ambrosy et al. (2012) conducted a cohort in Heart failure with reduced ejection fraction or previous myocardial infarction (n=15,381). B-type natriuretic peptide (BNP) assessment and levels vs. No BNP assessment or lower BNP levels was evaluated on Utilization of guideline-recommended heart failure therapies. BNP was measured in only 27.4% of outpatients with reduced LVEF, and its assessment or level did not increase the utilization of guideline-recommended heart failure therapies.